Bolt Biotherapeutics Net Income
| BOLT Stock | USD 4.95 0.03 0.61% |
As of the 16th of February 2026, Bolt Biotherapeutics shows the Downside Deviation of 4.04, risk adjusted performance of 0.0263, and Mean Deviation of 3.08. Bolt Biotherapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.
Bolt Biotherapeutics Total Revenue |
|
Gross Profit | Market Capitalization | Enterprise Value Revenue 0.2272 | Revenue | Earnings Share (22.21) |
| Last Reported | Projected for Next Year | ||
| Net Loss | -56.8 M | -59.6 M | |
| Net Loss | -79.3 M | -83.3 M | |
| Net Loss | -56.8 M | -59.6 M | |
| Net Loss | (1.49) | (1.56) |
Bolt | Net Income | Build AI portfolio with Bolt Stock |
The evolution of Net Income for Bolt Biotherapeutics provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Bolt Biotherapeutics compares to historical norms and industry peers.
Latest Bolt Biotherapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of Bolt Biotherapeutics over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Bolt Biotherapeutics financial statement analysis. It represents the amount of money remaining after all of Bolt Biotherapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Bolt Biotherapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Bolt Biotherapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (63.12 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Bolt Net Income Regression Statistics
| Arithmetic Mean | (37,116,042) | |
| Coefficient Of Variation | (83.71) | |
| Mean Deviation | 27,808,520 | |
| Median | (11,589,000) | |
| Standard Deviation | 31,069,561 | |
| Sample Variance | 965.3T | |
| Range | 87M | |
| R-Value | (0.79) | |
| Mean Square Error | 387.5T | |
| R-Squared | 0.62 | |
| Significance | 0.0002 | |
| Slope | (4,858,854) | |
| Total Sum of Squares | 15445.1T |
Bolt Net Income History
Other Fundumenentals of Bolt Biotherapeutics
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Bolt Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Bolt Biotherapeutics is extremely important. It helps to project a fair market value of Bolt Stock properly, considering its historical fundamentals such as Net Income. Since Bolt Biotherapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Bolt Biotherapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Bolt Biotherapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Is there potential for Biotechnology market expansion? Will Bolt introduce new products? Factors like these will boost the valuation of Bolt Biotherapeutics. Projected growth potential of Bolt fundamentally drives upward valuation adjustments. Understanding fair value requires weighing current performance against future potential. All the valuation information about Bolt Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (22.21) | Revenue Per Share | Quarterly Revenue Growth 0.901 | Return On Assets | Return On Equity |
The market value of Bolt Biotherapeutics is measured differently than its book value, which is the value of Bolt that is recorded on the company's balance sheet. Investors also form their own opinion of Bolt Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Bolt Biotherapeutics' true underlying value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Because Bolt Biotherapeutics' market value can be influenced by many factors that don't directly affect Bolt Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Bolt Biotherapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Bolt Biotherapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Bolt Biotherapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Bolt Biotherapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Bolt Biotherapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Bolt Biotherapeutics.
| 11/18/2025 |
| 02/16/2026 |
If you would invest 0.00 in Bolt Biotherapeutics on November 18, 2025 and sell it all today you would earn a total of 0.00 from holding Bolt Biotherapeutics or generate 0.0% return on investment in Bolt Biotherapeutics over 90 days. Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents... More
Bolt Biotherapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Bolt Biotherapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Bolt Biotherapeutics upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 4.04 | |||
| Information Ratio | 0.0057 | |||
| Maximum Drawdown | 18.32 | |||
| Value At Risk | (6.86) | |||
| Potential Upside | 8.22 |
Bolt Biotherapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Bolt Biotherapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Bolt Biotherapeutics' standard deviation. In reality, there are many statistical measures that can use Bolt Biotherapeutics historical prices to predict the future Bolt Biotherapeutics' volatility.| Risk Adjusted Performance | 0.0263 | |||
| Jensen Alpha | 0.0557 | |||
| Total Risk Alpha | (0.22) | |||
| Sortino Ratio | 0.0059 | |||
| Treynor Ratio | 0.1792 |
Bolt Biotherapeutics February 16, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0263 | |||
| Market Risk Adjusted Performance | 0.1892 | |||
| Mean Deviation | 3.08 | |||
| Semi Deviation | 3.85 | |||
| Downside Deviation | 4.04 | |||
| Coefficient Of Variation | 4426.53 | |||
| Standard Deviation | 4.15 | |||
| Variance | 17.21 | |||
| Information Ratio | 0.0057 | |||
| Jensen Alpha | 0.0557 | |||
| Total Risk Alpha | (0.22) | |||
| Sortino Ratio | 0.0059 | |||
| Treynor Ratio | 0.1792 | |||
| Maximum Drawdown | 18.32 | |||
| Value At Risk | (6.86) | |||
| Potential Upside | 8.22 | |||
| Downside Variance | 16.34 | |||
| Semi Variance | 14.8 | |||
| Expected Short fall | (3.37) | |||
| Skewness | 0.1537 | |||
| Kurtosis | 0.1303 |
Bolt Biotherapeutics Backtested Returns
Bolt Biotherapeutics appears to be slightly risky, given 3 months investment horizon. Bolt Biotherapeutics secures Sharpe Ratio (or Efficiency) of 0.0475, which signifies that the company had a 0.0475 % return per unit of risk over the last 3 months. We have found twenty-nine technical indicators for Bolt Biotherapeutics, which you can use to evaluate the volatility of the firm. Please makes use of Bolt Biotherapeutics' Downside Deviation of 4.04, risk adjusted performance of 0.0263, and Mean Deviation of 3.08 to double-check if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Bolt Biotherapeutics holds a performance score of 3. The firm shows a Beta (market volatility) of 0.47, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Bolt Biotherapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Bolt Biotherapeutics is expected to be smaller as well. Please check Bolt Biotherapeutics' downside variance, and the relationship between the sortino ratio and accumulation distribution , to make a quick decision on whether Bolt Biotherapeutics' price patterns will revert.
Auto-correlation | 0.11 |
Insignificant predictability
Bolt Biotherapeutics has insignificant predictability. Overlapping area represents the amount of predictability between Bolt Biotherapeutics time series from 18th of November 2025 to 2nd of January 2026 and 2nd of January 2026 to 16th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Bolt Biotherapeutics price movement. The serial correlation of 0.11 indicates that less than 11.0% of current Bolt Biotherapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.11 | |
| Spearman Rank Test | -0.55 | |
| Residual Average | 0.0 | |
| Price Variance | 0.34 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Bolt Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Bolt Biotherapeutics reported net income of (63.12 Million). This is 118.49% lower than that of the Biotechnology sector and 190.11% lower than that of the Health Care industry. The net income for all United States stocks is 111.05% higher than that of the company.
Bolt Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Bolt Biotherapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Bolt Biotherapeutics could also be used in its relative valuation, which is a method of valuing Bolt Biotherapeutics by comparing valuation metrics of similar companies.Bolt Biotherapeutics is currently under evaluation in net income category among its peers.
Bolt Biotherapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Bolt Biotherapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Bolt Biotherapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Bolt Biotherapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Bolt Biotherapeutics that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Bolt Biotherapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Bolt Biotherapeutics' value.| Shares | Adar1 Capital Management Llc | 2025-06-30 | 10.8 K | Blackrock Inc | 2025-06-30 | 10.6 K | Morgan Stanley - Brokerage Accounts | 2025-06-30 | 3.6 K | Goss Wealth Management Llc | 2025-06-30 | 483 | Tower Research Capital Llc | 2025-06-30 | 395 | Bank Of America Corp | 2025-06-30 | 282 | Ubs Group Ag | 2025-06-30 | 183 | Fmr Inc | 2025-06-30 | 121 | Jpmorgan Chase & Co | 2025-06-30 | 43.0 | Vivo Capital, Llc | 2025-06-30 | 176.1 K | Tang Capital Management Llc | 2025-06-30 | 166.9 K |
Bolt Fundamentals
| Return On Equity | -0.82 | ||||
| Return On Asset | -0.32 | ||||
| Operating Margin | (3.55) % | ||||
| Current Valuation | 1.18 M | ||||
| Shares Outstanding | 1.92 M | ||||
| Shares Owned By Insiders | 6.66 % | ||||
| Shares Owned By Institutions | 35.60 % | ||||
| Number Of Shares Shorted | 1.6 K | ||||
| Price To Earning | 36.55 X | ||||
| Price To Book | 0.30 X | ||||
| Price To Sales | 1.83 X | ||||
| Revenue | 7.69 M | ||||
| Gross Profit | (30.07 M) | ||||
| EBITDA | (66.45 M) | ||||
| Net Income | (63.12 M) | ||||
| Cash And Equivalents | 176.34 M | ||||
| Cash Per Share | 4.68 X | ||||
| Total Debt | 25.21 M | ||||
| Debt To Equity | 0.11 % | ||||
| Current Ratio | 9.73 X | ||||
| Book Value Per Share | 16.72 X | ||||
| Cash Flow From Operations | (61.29 M) | ||||
| Short Ratio | 0.07 X | ||||
| Earnings Per Share | (22.21) X | ||||
| Target Price | 22.0 | ||||
| Number Of Employees | 40 | ||||
| Beta | 0.92 | ||||
| Market Capitalization | 9.5 M | ||||
| Total Asset | 99.63 M | ||||
| Retained Earnings | (427.4 M) | ||||
| Working Capital | 34.96 M | ||||
| Current Asset | 53.49 M | ||||
| Current Liabilities | 9.12 M | ||||
| Net Asset | 99.63 M |
About Bolt Biotherapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Bolt Biotherapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bolt Biotherapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bolt Biotherapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Bolt Stock Analysis
When running Bolt Biotherapeutics' price analysis, check to measure Bolt Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bolt Biotherapeutics is operating at the current time. Most of Bolt Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Bolt Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bolt Biotherapeutics' price. Additionally, you may evaluate how the addition of Bolt Biotherapeutics to your portfolios can decrease your overall portfolio volatility.